Healthy
Conditions
Keywords
Drug Safety
Brief summary
A randomised, double-blind, placebo-controlled, phase I study in healthy subjects. Safety, pharmacokinetic and pharmacodynamic data will be collected.
Interventions
DRUGUE2343
Oral capsule
DRUGPlacebo
Oral capsule
Sponsors
Wellcome Trust
Simbec Research
University of Edinburgh
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male and female subjects between 18 and 65 years of age (inclusive). * Female subject is postmenopausal or surgically sterilized or had a hysterectomy. * Female subject with negative pregnancy test. * Male subjects willing to use an effective method of contraception, if applicable (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) from Day 1 until 3 months afterwards. * Subject with a Body Mass Index (BMI) of 18-30 kg/m2. Body Mass Index = Body weight (kg) / \[Height (m)\]2. * Subject with no clinically significant abnormal serum biochemistry, haematology and urine examination values or results suggesting an infectious or other systemic disorder. The parameters to be measured will include those shown in Appendix 2. The Simbec normal ranges are shown in Appendix 3. * Subject with a negative urinary drugs of abuse screen (Appendix 2) (N.B. a positive alcohol result may be repeated at the discretion of the Investigator). * Subject with negative HIV and Hepatitis B and C results. * Subject with no clinically significant abnormalities in 12-lead electrocardiogram (ECG). * no clinically significant abnormalities in vital signs. * willing and able to comply with the requirements of the protocol. * satisfy a medical examiner about fitness to participate in the study. * provide written informed consent to participate in the study. * Smokers are eligible to participate in the study.
Exclusion criteria
* Relevant abnormality in medical history or on examination, including history of dementia, or other psychiatric, neurological, immunological, respiratory or cardiovascular disorder. Particularly exclude subjects with signs of peripheral neuropathy. Abnormal laboratory findings suggesting the presence of a systematic disorder. * Participation in a clinical study of an unlicensed drug in the previous 4 months, or a marketed drug study within the previous 3 months. (N.B. washout period between trials defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study). * Known allergies, including allergy to chemicals like and excipients associated with UE2343. * Recent or clinically significant history of drug or alcohol abuse. * Blood donation greater than 500 ml in the previous 3 months. * Inability to communicate well with the Investigator (i.e., language problem, poor mental development or impaired cerebral function). * Receipt of regular prescribed medication within 7 days of the first study day and / or receipt of vitamins, minerals, herbal remedies and nutritional supplements within 7 days of the first study day. Subjects taking long lasting drugs more than 7 days before the study may be excluded at the physician's discretion. Inclusion of subjects who have taken over the counter drugs during this period will be reviewed on a case-by-case basis in relation to the safety aspects and objectives of this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and tolerability of UE2343 in healthy male/female subjects | At each dose | Days 1-2 at each dose: * 12 lead ECG * Vital signs * Symptom led clinical assessment (day 1 only) * Routine laboratory assessments Days 3-6 at each dose: * 12 lead ECG * Vital signs * Routine laboratory assessments Day 10 at each dose: * 12 lead ECG * Vital signs * Routine laboratory assessments * Physical examination * Pregnancy test |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic parameters of UE2343 and pharmacodynamic exposure | At each dose | Days 1-2 at each dose: * Blood and urine samples for measurement of UE2343 * Blood samples for adrenal androgens * Blood samples for ACTH and cortisol * Urine samples for urinary free steroids Days 3-6 at each dose: * Blood and urine samples for measurement of UE2343 * Blood samples for adrenal androgens * Blood samples for ACTH and cortisol * Urine samples for urinary free steroids |
Countries
United Kingdom
Outcome results
None listed